Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?
GROUND & AIMS: Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease with a variable clinical course. Identification of serologic markers associated with increased risk of liver failure would assist in management of PBC patients. The objective of this study was to identify antinuclear antibody (ANA) markers that may be used to predict PBC outcome. METHODS: Indirect immunofluorescence was used to identify ANAs in 492 PBC patients. chi2 and Kaplan-Meier analyses were used to examine the association between ANAs and liver failure. RESULTS: A greater percentage of ANA-positive, compared to ANA-negative, PBC patients developed liver failure (41% vs 25%, P = .005). The presence of anti-centromere antibodies was associated with liver failure (anti-centromere antibody positive vs negative, 58% vs 33%, P = .001). The time to liver failure was shorter in ANA-positive, compared with ANA-negative, patients (log rank score 5.8, P = .02). After 8.9 years (the median follow-up for pa
Related Questions
- DO PATIENTS WITH ANTI-MITOCHONDRIAL ANTIBODY-NEGATIVE PRIMARY BILIARY CIRRHOSIS FAIR POORLY AFTER LIVER TRANSPLANTATION?
- Should surveillance for hepatocellular carcinoma be increased in patients with cirrhosis and small liver nodules?
- Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?
